Santalis Pharmaceuticals issued patent for the use of sandalwood oil to treat cancers
Patent covers East Indian sandalwood oil-containing compositions that can be used to treat a variety of cancers.
Santalis Pharmaceuticals has announced the issuance by the Japanese Patent Office of a patent that covers sandalwood oil-containing compositions that can be used to treat a variety of cancers. The patent for invention number 5,972,797 includes claims that protect compositions for treatment of solid tumours, including bladder cancer; it also covers preventing the progression of actinic keratoses (AK) to squamous cell carcinoma (SCC).
Dr Paul Castella, CEO of Santalis Pharmaceuticals, said: “We’re very pleased that the first patent issued to us following acquisition by TFS Corporation protects compositions intended to treat life-threatening diseases. Obtaining patent protection for natural products is very challenging, and the issuance of this important patent validates our strategy of protecting novel compositions, formulations and uses of our pharmaceutical-grade East Indian sandalwood oil.”
East Indian sandalwood oil (EISO) is currently being studied in several Phase II clinical trials in Australia and the US for treatment of various skin conditions such as psoriasis, warts, atopic dermatitis and molluscum contagiosum. In addition, a mouth rinse containing EISO is being evaluated in a Phase II clinical trial for prevention of oral mucositis in head and neck cancer patients undergoing high dose radiation therapy.
EISO is an essential oil with a long history of use in traditional medicine and its broad range of biological activities and excellent safety profile make it an attractive drug candidate for clinical development in a variety of indications. Dr Corey Levenson, Santalis’ Chief Scientific Officer, said: “Most of our clinical efforts to date have focused on dermatology and EISO’s anti-inflammatory and anti-infective properties. This patent underscores the importance of our research on EISO’s novel anti-proliferative effects and its potential for use in the treatment of cancer.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance